Navigation Links
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
Date:12/20/2013

SYDNEY, Dec. 20, 2013 /PRNewswire/ -- Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).

(Logo:  http://photos.prnewswire.com/prnh/20131220/NY36990LOGO )

The research program is focused on the super-benzopyran drug, Trilexium (Trx).

The brain cancer program parallels that of the Company's efforts in the area of ovarian cancer through its joint venture, CanTx Inc, with Yale University.

CanTx has identified a Trilexium derivative (Trx-1) as having equipotent killing ability of both ovarian cancer stem cells and ovarian cancer somatic cells, raising the prospect for the first time of being able with the one agent to kill the full hierarchy of cells within an ovarian cancer. The CanTx strategy is to bring Trx-1 into the clinic in the near-term as a generic treatment for late-stage ovarian cancer, but then to use the Trx pharmacophore to create a panel of drugs capable of killing ovarian cancer cells with specific genotypes, a further unique feature of this technology platform.

The brain cancer program has the same R&D and commercial objectives. The near-term goal is to bring Trilexium into the clinic as a generic treatment for GBM that has failed to respond to Temozolomide, the only drug approved for GBM. The longer-term goal is to identify a panel of drugs capable of providing a personalized approach to GBM chemotherapy.

The program is based on the high potency of Trilexium against GBM cells, with both GBM stem cells and somatic cells being killed at equivalent dosages.

Progression of GBM following radiotherapy and chemotherapy is believed to result from the regrowth of cancer stem cells that are chemo-resistant. Recurrent tumor cells, like their parent GBM stem cells, are highly drug-resistant and with increased aggression, accounting for the poor prognosis associated with GBM.

Dr David Brown, Novogen Group CSO, said, "The collaborative effort to date has focused on bringing Trilexium into the clinic for the treatment of GBM, and that goal will continue with the aim of bringing that agent into the clinic in early 2015."

"The expansion of the collaboration to include Cornell takes the program to the next level, which is to achieve personalized chemotherapy for patients with GBM. The objective is to identify a panel of Trx analogs that target individual GBM mutations within the genotype spectrum that characterises GBM malignancies. That data then will inform our clinical objective which is to match the best drug candidate to an individual tumor genotype."  

"WCMC has particular skills in identifying the genotype of explants from fresh biopsies of GBM tumors. We will be utilizing this ability to screen Trilexium analogs for activity against a wide range of individual tumors," Brown added.

About Glioblastoma

Glioblastoma multiforme is the most common and aggressive form of primary brain tumor. Worldwide, in developed countries, an estimated 3.5 cases per 100,000 people are diagnosed per year. Glioblastoma is one of the cancers most resistant to treatments and is associated with extremely poor prognosis. Despite therapeutic intervention (surgery/radiation/chemotherapy), glioblastoma remains a devastating disease with a median 2-year survival rate in the range of 10–25%.

About Novogen

Novogen Ltd is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN').  The Company is based in Sydney, Australia, and with a US office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc with the aim of developing personalized chemotherapy for patients with ovarian cancer.

Further information is available on the Company's web site, www.novogen.com


'/>"/>
SOURCE Novogen Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
2. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
3. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
4. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
5. Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
6. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
7. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
8. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
9. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
10. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
11. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , November 30, 2016 The global ... few players hold a dominant share in the overall ... Laboratories International, Inc., and Merck KGaA, held a lion,s ... Transparency Market Research observes that these companies are expected ... development products that are do not require rabbit pyrogen ...
(Date:11/30/2016)... VANCOUVER , Nov. 30, 2016 /PRNewswire/ -  Equicare ... coordination solutions, has been recognized as one of the ... 100, an annual international listing that distinguishes the top ... "We,ve pushed a great step forward this year continually ... growing our own customer base and team," says ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... Triangle Park, NC (PRWEB) , ... November 30, ... ... development company engaged in the development of a new orally administered treatment for ... testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):